Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma
نویسندگان
چکیده
منابع مشابه
Small B cell Non-Hodgkins Lymphoma in Pakistan.
OBJECTIVE To study the pattern of small B cell lymphomas in Pakistan. METHODS This descriptive study was carried out at the Aga Khan University Hospital pathology department including 1721 cases of Non-Hodgkins Lymphoma (NHL) diagnosed during a period of five years (1998-2002) and classified according to REAL/WHO classification. The antibodies used included Leukocyte Common Antigen (LCA), Pan...
متن کاملDevelopment of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...
متن کاملDevelopment of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...
متن کاملNon-Hodgkins Lymphoma presenting as Garcin’s Syndrome
An 80 year old man presented with a twelve month history of progressive multiple unilateral cranial nerve palsies. A gadolinium enhanced MRI scan of his head and neck was performed. This showed an extra-axial enhancing lesion, which enveloped the hemi-mandible at the level of the left inferior alveolar nerve, and a dumbbell shaped lesion within the cerebellopontine angle. An incisional biopsy w...
متن کاملRadioimmunotherapy for B-cell non-hodgkin lymphomas.
BACKGROUND Radioimmunotherapy (RIT) is a safe and effective therapeutic option for patients with indolent B-cell non-Hodgkin lymphomas (NHL), in both up-front and relapsed/refractory settings. Two approved agents (90Y-ibritumomab tiuxetan and 131I-tositumomab) are available in the United States. Both target CD20 with similar clinical outcomes but with unique clinical considerations and radiatio...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Oncology
سال: 2013
ISSN: 2234-943X
DOI: 10.3389/fonc.2013.00177